Daily Stock List
Multi-Corp. International, Inc. (MULI)
Real Pennies reported earlier this month on Multi-Corp. International, Inc. (MULI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Multi-Corp. International, Inc. is an Exploration and Production (E&P) company with corporate headquarters in Denver City, Texas. The Company is focusing on developing and acquiring oil and gas resources initially in New Mexico and subsequently throughout North America. Multi-Corp. owns a 100 percent Working Interest (WI) in 2,800 acres in the Cave Pool Unit and field. Multi-Corp. lists on the OTCQB.
The Cave Pool Unit property contains approximately 40 wells within Eddy County, New Mexico. These have produced; however, they are presently shut-in. The Cave Pool Unit property is within the prolific Artesia Vacuum Trend, within the Grayburg Jackson Pool. The Artesia Vacuum Trend play contains 13 reservoirs with over 1 MMBO cumulative production.
An independent reserve evaluation indicates estimated Proved light oil reserves of 386,000 STB having a Net Present Value (NPV) of $11,954,000 at 10 percent DCF/annum. It also indicates additional Probable reserves of 1,570,000 STB, having a value of $67,479,000 at 10 percent DCF/annum. The Current Net Present Value (NPV) of the P1 and P2 reserves are estimated to be worth combined approximately $79,433,000 – plus. This does not include the value in the P3 reserve.
Production of the reserves will be realized via drilling of wells on unexploited locations from the Grayburg sand identified on well logs of the existing wells on these lands. Some of the wells on these lands will be re-entered for production from previously uncompleted zones in the Grayburg reservoir.
The Company has a 100 percent WI in the Cave Pool Unit property. There are currently 32 wells that can produce approximately 40 BOPD, with 30 MCF based on 40 acre spacing. There are more than 100 possible drilling locations based upon 20 acre spacing. Multi-Corp has identified 10 wells that are currently shut-in. These will be returned to producing status within the first 60 days of operation.
Multi-Corp. International, Inc. (MULI), closed Wednesday's trading session at $0.905, up 64.55%, on 12,050 volume with 16 trades. The stock's 52-week low/high is $0.01/$11.50.
MEDL Mobile Holdings, Inc. (MEDL)
RedChip and SmallCapVoice reported this month on MEDL Mobile Holdings, Inc. (MEDL); FeedBlitz did earlier, and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
MEDL Mobile Holdings, Inc. (listed on the OTC Markets' OTCQB) develops, acquires and publishes a growing library of mobile applications (apps). These apps perform specific functions for the user on the Apple and Android platforms. The Company licenses their technology and performs custom development for key clients such as Monster.com, the New York Times Company, Teleflora, Telefonica and Medtronic.
Based in Fountain Valley, California, MEDL Mobile Holdings is establishing a business model in which they expect to generate multiple revenue streams. These streams include development fees, download and in-app purchases, advertising, sponsorship and licensing of technology. The Company enters into partnerships to mobilize and monetize Intellectual Property (IP) with prominent names such as Encyclopedia Britannica, MTV's Pauly D, Cheech & Chong, Rampage Jackson and Marlee Matlin.
The Company's growing Mobile Brain collects user analytics. It processes user data to create better distribution and monetization of mobile applications. MEDL Mobile's Software Development Kit (SDK) consists of an expanding collection of tools that have undergone design to help developers to better market and monetize their mobile applications.
Yesterday, MEDL Mobile announced that the Company joined forces with Specific Media to supply mobile video advertising for MEDL Mobile's recently launched social media platform, "Hang w/." The Patent Pending Hang w/ platform allows live real-time video to be broadcast from one phone to many. Broadcasters earn a percentage of the advertising revenue-generated based upon the number of followers who are "Hanging w/" them.
The agreement gives Specific Media the exclusive rights to sell all unfilled advertising on the platform. MEDL Mobile Holdings retains the rights to partner directly with brands and advertising agencies to sell advertising and sponsorship for individual celebrities and for Hang w/ "channels" of content. Hang w/ is currently available on the Apple App Store. Hang w/ will be available for Android in Q2, 2013.
MEDL Mobile Holdings, Inc. (MEDL), closed Wednesday's trading session at $0.40, down 6.98%, on 115,040 volume with 36 trades. The average volume for the last 60 days is 196,803 and the stock's 52-week low/high is $0.071/$1.07.
Eco-Trade Corp. (BOPT)
We are highlighting Eco-Trade Corp. (BOPT), here at the QualityStocks Daily Newsletter.
Listed on the OTC Markets' OTCQB, Eco-Trade Corp. is an independent oil and gas exploration company. Eco-Trade has rights to the exploration, drilling and production rights on a property in Lewis & Clark County in Montana, near Great Falls. It totals more than 5,800 acres (named the South Bakken Prospect). Founded in 1992, Eco-Trade has their corporate headquarters in Washington, D. C.
The South Bakken Prospect has an estimated reserve potential of between 80 to 120 millions of barrels of oil recoverable. The South Bakken Prospect is in a prime area of the Bakken Fairway in Townships 19-20 North and Ranges 5-6-7 West. The Bakken Fairway was initially discovered and drilled in Alberta. It now extends deep into northwest Montana into Lewis & Clark County where it is bordered by the Rocky Mountain Thrust Zone on the west and the Sweetgrass Arch to the west.
This prospect lies within the important oil-producing zone where thermal maturity (Ro) is between 0.7 percent and 1.5 percent. Oil production begins when Ro is above 0.65 percent and slows when Ro is more than 1.3 percent. The Total Oil Content (T.O.C.) readings in the prospect area are high; they read between 7 percent and 14 percent. The water content of the Bakken in the area is low. As of October, 2011, there have been an estimated 48,000 total wells drilled in the Williston Basin to the Bakken/Three Forks, with an estimated 24 billion barrels of recoverable oil.
This week, Eco-Trade announced the addition of Mr. Chris Popoff, P. Eng., MBA, and Mr. Robert M. Price to the Company's Board of Directors. Mr. Popoff is the Co-Founder of Penumbra Energy. He is currently employed as a Senior Development Engineer with Athabasca Oil Sands Corp. Mr. Price is an accomplished Corporate Attorney in Washington D.C. He has 50 years experience in corporate affairs and he is very active in the D.C. Bar.
Eco-Trade Corp. (BOPT), closed Wednesday's trading session at $0.40, up 25.00%, on 281,063 volume with 56 trades. The average volume for the last 60 days is 48,624 and the stock's 52-week low/high is $0.08/$0.73.
GlyEco, Inc. (GLYE)
Red Chip reported yesterday on GlyEco, Inc. (GLYE), Greenbackers, PennyStocks24, SmallCap Network did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
GlyEco, Inc. is a green chemistry enterprise that established to bring to market their proprietary and patent-pending recycling technology. This technology is for transforming a hazardous waste into green products. GlyEco Technology™ can clean the polluted glycols from all five waste-producing industries. These five are HVAC, Textiles, Automotive, Airline and Medical. The Company's management team has an accomplished background in the solid waste industry, chemical engineering and glycol recycling. GlyEco's shares trade on the OTCQB; the Company is based in Phoenix, Arizona.
Glycols are synthetic liquid chemicals derived from crude oil and natural gas. The GlyEco technology recycles waste glycol to meet ASTM Type 1 specifications. The technology enables their clients to handle the removal of their waste glycol in a responsible and environmentally safe manner. The Company's technology removes challenging pollutants. These include esters, organic acids, high dissolved solids, as well as high undissolved solids. Their technology clears oil/hydrocarbons, additives and dyes that are usually found in used engine coolants.
GlyEco provides disposal clients documented compliance with EPA Hazardous Waste Manifest System and all State and Local regulations. The proprietary technology will allow the Company to expand their services beyond the used car antifreeze recycling market into four additional large industrial markets that create waste glycol.
This past January, GlyEco's Board of Directors announced that they elected Mr. Joe Ioia as a Director of the Company. Mr. Ioia is a leader in the emerging glycol recycling industry. He has a 40-year accomplished background in the petrochemicals and petroleum lubricants industries.
Recently, GlyEco announced the completion of $1.7 million in financing. This represents an extension of the previously announced offering that has raised $6.2 million for the Company since March 2012. Security Research Associates was GlyEco's non-exclusive placement agent in connection with this offering. GlyEco's intention is to use the proceeds from this offering to accelerate their aggressive growth plan. This includes investments in initial facility upgrades and increased processing capacity, and Phase I implementation of their patent-pending GlyEco Technology™.
GlyEco, Inc. (GLYE), closed Wednesday's trading session at $1.45, up 6.62%, on 28,253 volume with 28 trades. The stock's 52-week low/high is $0.99/$2.99.
OncoSec Medical, Inc. (ONCS)
Greenbackers, Stock Analyzer, and Real Pennies reported earlier on OncoSec Medical, Inc. (ONCS), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTCQB, OncoSec Medical, Inc. is a biopharmaceutical company based in San Diego, California. The Company is developing their advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers. The basis of OncoSec Medical's core technology is upon their proprietary use of an electroporation platform to enhance significantly the delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse).
OncoSec Medical's technology development includes the design and manufacture of medical-grade electrical pulse generators, treatment applicators, and software that maximize safety and efficacy for different clinical applications. The Company's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. OncoSec's objective is to complete enrolment for their Phase II melanoma program by the end of Quarter 1 of 2013.
ImmunoPulse and NeoPulse therapies address an unmet medical need and represent a potential solution for less invasive and less expensive therapies that can lessen detrimental effects resulting from presently available cancer treatments. Treatment of different solid cancers utilizing these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials.
The Company's technologies center on a proprietary process called electroporation. It uses an electrical pulse to create temporary pores in cancer cells. Clinically proven chemotherapeutics or gene-based cytokines subsequently undergo delivery by way of these pores. This allows for far more effective treatment - at substantially lower doses.
On Monday, OncoSec Medical announced that the Company published a blog post entitled "Building Relationships between Biotech Corporations and Academia" on President and CEO Mr. Punit Dhillon's blog site (punitdhillon.com) which was republished on TheChairmansBlog.com. Mr. Dhillon writes concerning the importance of integrating academic institutions and their research potential with the research and development (R&D) pipeline of biotechnology corporations.
In addition, on Monday, OncoSec Medical announced positive, durable response results in an update on interim data from their Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference on March 22, 2013 in New York, New York.
OncoSec Medical, Inc. (ONCS), closed Wednesday's trading session at $0.228, up 11.00%, on 845,659 volume with 137 trades. The stock's 52-week low/high is $0.14/$0.485.
Solar Wind Energy Tower, Inc. (SWET)
Today we are highlighting Solar Wind Energy Tower, Inc. (SWET), here at the QualityStocks Daily Newsletter.
Solar Wind Energy Tower, Inc. focuses on the design, development, and construction of Downdraft Towers that utilize benevolent and non-toxic natural elements to produce electricity and clean water in the U.S. and worldwide. The Company formerly went by the name Clean Wind Energy Tower, Inc. They changed their corporate name to Solar Wind Energy Tower, Inc., effective March 11, 2013. Solar Wind Energy, Inc. (Solar Wind Energy) is a wholly owned subsidiary of Solar Wind Energy Tower (based in Annapolis, Maryland).
Solar Wind Energy Tower has filed numerous patents that the Company believes will further enhance their innovative technology. Additionally, the Company's intention is to establish partnerships domestically and internationally to get these systems into more markets and meet growing worldwide demand for clean water and electricity.
Their subsidiary, Solar Wind Energy, formed to commercialize several proven, validated technologies and construction systems into a single large Solar Wind Downdraft Tower structure that produces abundant, inexpensive electricity. Their main goal and focus is to become a leading provider of clean, efficient green energy to global communities, at a reasonable cost, without the destructive residuals of fossil fuels. Their objective is to accomplish this while continuing to generate unique technological solutions for future electrical power requirements.
The Solar Wind Downdraft Tower is a hollow cylinder. It reaches into the hot, dry atmosphere heated by solar rays. The water introduced by the injection system near the top of the Tower evaporates and undergoes absorption by the hot, dry air. The air becomes cooler, denser and heavier than the outside warmer air. It falls through the cylinder at speeds up to and greater than 50 mph. It is diverted into wind tunnels surrounding the base of the Tower where turbines inside the tunnels power generators to make electricity.
In January 2013, the Company announced that they engaged a new consultant to analyze, assess and prepare an application for them to market the potential carbon credits that will result from a planned project in Mexico and Investment Tax Credits that should result from a project in Arizona.
Solar Wind Energy Tower, Inc. (SWET), closed Wednesday's trading session at $0.0251, up 73.10%, on 6,893,759 volume with 304 trades. The stock's 52-week low/high is $0.01/$0.08.
Katanga Mining Ltd. (KAT.TO)
Today's Financial News reported previously on Katanga Mining Ltd. (KAT.TO), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Listed on the Toronto Stock Exchange - Zug, Switzerland-based Katanga Mining Ltd. operates a major mine complex in the Democratic Republic of Congo (DRC). The Company produces refined copper and cobalt. Katanga has a large-scale copper-cobalt project with substantial high-grade mineral reserves and integrated metallurgical operations. The Company holds a 75 percent stake in two joint ventures with Gécamines, a state-owned mining company in the DRC.
Katanga Mining operates a large-scale copper-cobalt mine complex in the DRC through two joint ventures, Kamoto Copper Co. (KCC) and DRC Copper and Cobalt Project (DCP). KCC and DCP operate on adjacent properties in the DRC; they are working to create a major single-site copper and cobalt operation. KCC and DCP engage in the exploration, refurbishment and rehabilitation of the Kamoto/Dima mining complex (the Kamoto Project) and the KOV copper and cobalt mine, respectively in the DRC.
The Kamoto Project includes exploration and mining properties, the Kamoto concentrator, the Luilu metallurgical plant, the Kamoto underground mine, and two oxide open pit resources in the Kolwezi district of the DRC. In addition, Katanga additionally has a number of other mines and plants that may be operated initially or at a later stage in the Company's development. These include the open pit mines Mashamba East, Musonoie-T17 and Kananga.
Earlier this month, Katanga Mining announced their ore reserve and mineral resource estimates as at December 31, 2012. Overall, the Measured and Indicated mineral resource for their Kamoto Copper (KCC) decreased by 6.0 million tonnes. Changes in the Measured mineral resource for KTO and KOV Open Pit is a decrease of 1.7 million tonnes each at KTO and KOV Open Pit based on the depletion of the mineral resource because of mining in 2012.
Changes in the Indicated mineral resource for KOV Open Pit is a decrease of 2.6 million tonnes based on the depletion of the mineral resource because of mining in 2012. Changes in the Inferred mineral resource for KOV Open Pit is a decrease of 0.1 million tonnes based on the depletion of the mineral resource due to mining in 2012. There are no changes in the mineral resources reported for Mashamba East Open Pit, T-17 Open Pit, Kananga Mine and Tilwezembe Open Pit. Mining did not take place in these zones in 2012. Moreover, no geological work took place on these zones in 2012.
Katanga Mining Ltd. (KAT.TO), closed Wednesday's trading session at $0.76, even for the day, on 11,479 volume. The stock's 52-week low/high is $0.41/$1.11.
Bioheart, Inc. (BHRT)
Investor News Source, AwesomePennyPicks, Vantage Wire, AwesomePennyStocks, and PennyTrader Publisher reported previously on Bioheart, Inc. (BHRT), and we highlight the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in Sunrise, Florida, Bioheart, Inc. operates within the cardiovascular sector of the cell technology industry. They deliver cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. The Company's objectives are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations. Bioheart has numerous cell therapies in different stages of development that repair damaged hearts.
The Company focuses on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Bioheart uses diverse cell types to treat cardiovascular diseases. The Company's belief is that the unique qualities within the different cell types make them more advantageous to treat a specific disease. Bioheart owns or holds licenses or holds sub-licenses to an intellectual property (IP) portfolio consisting of approximately 19 patents and 19 patent applications in the U.S., and approximately 12 patents and 57 patent applications in foreign countries. These are all for use in the field of heart muscle regeneration.
Bioheart's lead product is MyoCell®. This is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for improving cardiac function in chronic heart failure patients. The MyoCell® muscle stem cell therapy procedure involves a physician removing a small amount of muscle from the patient's thigh. From this muscle specimen, muscle stem cells (myoblasts) are subsequently isolated, expanded using Bioheart's proprietary cell-culturing process, and injected directly into the scar tissue of the patient's heart.
The cells are delivered by an endoventricular needle-injection catheter during a minimally invasive procedure performed by an interventional cardiologist or vascular surgeon. The muscle stem cells populate the regions of scar tissue. The intention of them is to improve cardiac function by helping the heart muscle beat more efficiently.
In addition to MyoCell®, Bioheart products include MyoCell SDF-1; this product has received approval from the FDA to begin human clinical trials. The intention of MyoCell SDF-1 is to be an improvement to MyoCell. The Company's products also include MyoCath. This is a disposable needle injection catheter used for the delivery of biologic solutions to a targeted treatment site within the myocardium (inner wall of the heart). Additionally, Bioheart has applied to the FDA to begin trials using adipose derived stem cells or LipiCell™ in patients with chronic ischemic cardiomyopathy.
This month, Bioheart announced that they secured the necessary funding for the ANGEL trial. This trial will initiate in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). The phase one trial will test the safety and efficacy of LipiCell™ in congestive heart failure patients.
Today, Bioheart announced that the Company is preparing to request of the FDA's Center for Biologics Evaluation and Research (CBER) permission to allow access to investigational drugs outside of a clinical trial setting. Expanded access, or "compassionate use," is the use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options.
Bioheart, Inc. (BHRT), closed Wednesday's trading session at $0.039, down 2.50%, on 14,864,449 volume with 380 trades. The average volume for the last 60 days is 715,450 and the stock's 52-week low/high is $0.005/$0.0565.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.30, up 15.38%, on 329,929 volume with 89 trades. The stock’s average daily volume over the past 30 days is 148,705, and its 52-week low/high is $0.161/$0.5895.
International Stem Cell Corp. offered markets a look at the Q4 financials today (ended Dec 31), including highlights like a 42% total jump in revenue compared to Q4 2011, realization of a 14% increase in sales by the Lifeline Cell Technology unit, and an 8% tightening of development expenses due to shored up cost of sales and consulting expense on R&D. The company also covered key operational advancements like the stunning successes of the Parkinson's program, which saw the development of a new and highly-efficient manufacturing method for the neuronal cells. Also among the highlights was the addition of fifteen human lines to the stem cell bank via three new cGMP-grade stem cell lines, the development of a new protein-based technology to derive iPS cells without the use of viruses (as in traditional methods), and the important USPTO patent issuance covering their creation of liver and pancreas precursor cells.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Fourth Quarter 2012 Financial Results and Provides Business Update
International Stem Cell Corp. to Host Conference Call Thursday, March 28 to Discuss Year End 2012 Financial Results and Provide Business Update
International Stem Cell Corp. to Host Conference Call on Friday, March 22 to Discuss Positive Study Data of Parkinson's Disease
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.168, up 4.87%, on 133,044 volume with 53 trades. The stock’s average daily volume over the past 60 days is 198,356, and its 52-week low/high is $0.15/$0.295.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Receives ISO Certification for Excellagen
Cardium's To Go Brands® to Launch Expanded VitaRocks® kids Vitamin Line With New Retail Distribution
Cardium's Excellagen® Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0889, up 0.11%, on 1,684,349 volume with 71 trades. The stock’s average daily volume over the past 60 days is 4,679,829, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop
Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards
Advaxis’ ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma
VentriPoint Diagnostics Ltd. (VPTDF)
The QualityStocks Daily Newsletter would like to spotlight VentriPoint Diagnostics Ltd. (VPTDF). Today, VentriPoint Diagnostics Ltd. closed trading at $0.094, even for the day, on 60,000 volume with 4 trades. The stock’s average daily volume over the past 30 days is 27,306, and its 52-week low/high is $0.073/$0.187.
VentriPoint Diagnostics Ltd. (VPTDF) leverages knowledge-based techniques to make heart analysis more convenient and less expensive. Having already installed multiple VMS™ analysis systems for heart testing in leading cardiac centers in Europe, Canada and the United States, the company is currently focused on expanding the applications of its technology beyond congenital heart disease in adults and children.
VMS™ is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. The company designed its analysis system to be used for all major heart diseases, including pulmonary hypertension, cardiovascular disease, and heart failure. Canada and Europe (CE Mark) have granted approval for the sale of the VMS™ diagnostic tool, and VentriPoint is pursuing the US-FDA approval through the 510(k) process.
The company’s VMS™ analysis systems eliminate all the disadvantages of an MRI scan, including a long wait list, the one-hour scan time, the claustrophobic environment, the requirement of a general anesthetic for children, the lengthy heart analysis process, and the need for a second trip to the hospital. Offering better efficiency and cost savings, VMS™ offers the healthcare industry a superior method of heart visualization.
The management team executing VentriPoint’s business strategy retains extensive experience in both healthcare technology and business development. Many expansion opportunities exist for the company’s technology with a total market potential exceeding $1 billion. As a leader in the clinical diagnostics market, the company is well positioned to meet the well-defined clinical need for efficient, accurate, and inexpensive heart analysis. Disclaimer
VentriPoint Diagnostics Ltd. Company Blog
VentriPoint Diagnostics Ltd. News:
VentriPoint Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease
VentriPoint Announces $2 Million Unit Private Placement
VentriPoint Receives US-FDA Acceptance of 510 (K) Submission for Pulmonary Arterial Hypertension
International Stem Cell Corp., a biotechnology company focused on therapeutic and biomedical products using human parthenogenetic stem cells (hpSCs), announced its financial results for the three and twelve months ended December 31, 2012.
FY 2012 Highlights:
• Made significant progress in Parkinson’s program including the development of a new highly-efficient manufacturing method for generating neuronal cells and conducted preliminary toxicology and pharmacology studies in animals.
• Added world-recognized neurobiologist, Dr. Evan Y. Snyder, head of the FDA’s Cellular, Tissue and Gene Therapies Advisory Committee, Director of the Stem Cells and Regenerative Biology Program at Sanford Burnham Medical Research Institute, as an non-compensated member of our Board of Advisors.
• Expanded stem cell bank to a total of fifteen human lines by adding three new cGMP-grade stem cell lines, derived in the ISCO’s California facility, capable of immune-matching millions of individuals.
• Developed a new protein-based technology to derive iPS cells without the use of viruses as in traditional methods.
• Received a key patent issued by the USPTO covering the creation of liver and pancreas precursor cells. Performed hybrid toxicology/pharmacology study in a rodent model of Crigler-Najjar disease.
• Progressed the Cornea program by the development of endothelial-like cells for 3D corneal structures as part of our Indian collaboration.
• Realized 14% increase in sales in Lifeline Cell Technologies to $2.38 million for 2012.
• Significantly expanded marketing activities, brand awareness, diversified sales channels and launched new eye firming serum in Lifeline Skin Care, all of which lead to higher sales in second half of the year.
• Raised $7.03 million and reduced G&A expenses by 11% compared with 2011.
Fourth quarter revenue was reported at $1.25 million compared to $1.06 million for the same period in 2011. Sales for Lifeline Skin Care (LSC) and Lifeline Cell Technology (LCT) increased by 39% and 3%, respectively. According to today’s press release, LSC and LCT accounted for 48% and 52% of total revenue in the three months ended December 31, 2012.
Development expenses were down by 8% to $3.65 million. The company attributed the decrease to reductions in cost of sales and consulting expenses relating to its research and development projects, partially offset by an increase in sales and marketing spending. General and administrative expenses totaled $1.89 million, reflecting relatively constant expense compared to the prior year.
Sales for the entire year of 2012 were $4.57 million compared to $4.53 million in 2011. LCT sales totaled $2.38 million, up 14% from 2011, representing a little over half of total revenue in 2012. LSC revenues were $2.19 million compared to $2.45 million in 2011.
Cost of sales totaled $1.27 million, or 28% of revenue, compared to $1.62 million, or 36% of revenue, a year earlier. The company added efficiencies to its manufacturing and supply chain management for both LSC and LCT.
Net loss from development activities was $9.81 million, compared to $11.36 million in 2011, a 14% reduction primarily due to favorable reductions in cost of sales, research and development expenses, and general and administrative costs.
“We have made excellent progress in our therapeutic development programs, being able to start our non-human primate study in our Parkinson’s disease program earlier than anticipated, and report top line data at the American Academy of Neurology Annual Meeting,” commented Dr. Andrey Semechkin, ISCO’s CEO and Co-Chairman. “In addition, our results for the fourth quarter reflect good progress by LSC and LCT both in terms of growing sales and implementing their strategies. Particularly pleasing is LSC’s continued quarterly revenue growth as they aim to diversify their sales channels, and LCT’s strong annual results. General and administrative expenses continued to decrease reflecting our increased focus on cost containment. Looking ahead to the next twelve months, we anticipate our R&D expenses to increase as we expand our pharmacology and safety studies and our Parkinson’s program moves closer to our targeted IND filing in early 2014.”
Conference Call and Webcast Details
Date: Thursday, March 28, 2013
Time: 11:00 a.m. Eastern Time
Conference Call Dial-in Numbers
Participants from US Domestic: 1-877-941-2068
Participants from International: 1-480-629-9712
Conference ID: 4610666
The company encourages participants to log into the call 10 minutes prior to the start time.
For more information, visit www.internationalstemcell.com
One of the challenges facing heart doctors is working with people having congenital heart disease (CHD). It’s a growing problem that involves unique issues. Though CHD is usually associated with children, a recent article by Michael O’Riordan in Clinical Cardiology (http://dtg.fm/5AjT) references a report indicating that the frequency of hospitalizations among adults for congenital defects has grown twice as fast as for children, with annual adult admissions now over a third of total CHD admissions. Among other factors, people who used to die young from such problems are now often living well into adulthood. The result is a growing burden on the healthcare system.
Accurate analysis of the heart can be a difficult and expensive process, and involves special issues dealing with the many children afflicted with the disease. Adding to the problem is the fact that people with CHD almost always have right heart defect, which can pose special challenges for accurate analysis. The unconventional shape, position, and size of the right ventricle has made it difficult to obtain reliable data regarding pump volume and cardiac function.
VentriPoint Diagnostics, a Canadian-based medical device company, offers what could be a breakthrough solution to the problems of accurate and comprehensive heart function analysis. The company’s new imaging system, called “Angelo,” is the only software available that offers comprehensive 3D imaging as quickly and cost-effectively, including the right heart. The system uses anatomical “dots” to build a 3D model of the heart, calculating such functional information as heart volumes, cardiac output, and ejection fraction, all within only 10 minutes, using conventional 2D ultrasound input.
The technology is based upon a patented approach known as knowledge-based reconstruction. The software can be added to any 2D ultrasound equipment, providing results that are faster, easier, and less expensive than any other heart assessment techniques. For both patients and doctors dealing with CHD, it offers new hope, and has already been approved for congenital heart disease application in Canada and Europe, with clinical trials currently finishing up in the U.S.
For more information, visit www.ventripoint.com
Viscount has been controlling facility access for over 30 years, but has today become a leader in the application of advanced IT technology to physical access. The foundation for this revolution is the company’s MESH Security Operating Platform, designed to reduce the complexity and cost of facility protection through the replacement of traditional hardware with IT servers and accessories. The result is more security for less money. The MESH platform is able to manage a large array of card access, intercom, video, and other devices, by using a common interface layer, and provides a critical and flexible foundation for Viscount products.
• Freedom – Viscount’s newest product, Freedom, is the world’s most advanced physical access control system. The system engages Microsoft’s Active Directory to offer unified logical and physical access control. It eliminates the need for costly dedicated access control panels, and removes cyber security risks associated with this legacy technology.
• Freedom Facility Friend – This is an add-on module to facilitate access control through manned entrances. Applications include photo badging, visitor management, incident reporting, scheduling, banned visitors, as well as lost-and-found. As a web-based application, it can link and manage an unlimited number of corporate locations.
• Freedom Cube – This is a software processing unit for the Freedom IP based system, with each Cube acting as a standalone access control system for up to 20 entrances. For more elaborate requirements, the Cubes can work as a local database appliance to provide redundant database support.
• Freedom Encryption Bridge – This is an IT platform that uses IP card reader bridges designed to eliminate the need of access control panels. You can turn any card reader into an IP device by connecting it to a Freedom Encryption Bridge.
• Freedom Raid Server – This is a premium central processing option. Each FRS can act as a standalone access control system, or can be used as a distributed database appliance working with other Freedom servers sharing data across a network.
• Freedom Mobile – This is Viscount’s latest software application. It eliminates the need for cards or readers by using a mobile device to open doors. It can also be used to track people or assets, plus can be used as an emergency notification system.
For additional information, visit www.Viscount.com
Why do pharmaceutical drugs cost so much? Because pharmaceutical companies waste so much money and time developing them.
But these companies can be excused for wasting hundreds of millions of dollars and years of work developing drugs that won’t be approved for use. The conventional method for initially testing the effectiveness and toxicity of these drugs – testing on animals – is terribly ineffective.
While scientific models like animals can provide a clue of how a drug might affect a human, they can never truly replicate the effects of giving the drug to people. Drugs that might not work in animal models – or even cause harmful effects – could produce an entirely different outcome when given to humans. But before government regulators will allow a drug to be tested on humans, it has to be proven safe in costly clinical trials with animal models or in vitro cell culture testing systems.
Drugs are scrapped every year by pharmaceutical companies after toxicity issues are discovered. The drugs are soon forgotten as the companies move on to find the next “wonder drug.” If scientists had a more accurate scientific model to perform initial tests on, they would be able to better predict which drugs are safe and which aren’t long before large investments are made.
A San Francisco-based biotechnology company, VistaGen Therapeutics, is focused on changing all of this through its novel platform Human Clinical Trials in a Test Tube™. The platform uses proprietary and exclusively-licensed stem cell technologies, some co-developed by Dr. Gordon Keller, a world renowned stem cell scientist.
In addition to providing toxicity predations for new drugs, the platform is designed to “rescue” once-promising small molecule drug candidates that were shelved because they exhibited negative effects in studies using conventional scientific models. Development of these drug candidates are often halted due to signs of heart or liver toxicity or metabolism issues during tests using scientific models like animals or in vitro cell culture testing systems.
The Human Clinical Trials in a Test Tube platform enables controlled differentiation of pluripotent stem cells into mature human cells, which are a more accurate model for clinical trials. The platform helps scientists determine if the negative effects experienced in previous trials with conventional models apply to humans. It can also be used to help generate new, safer variants in combination with modern medicinal chemistry.
By developing scientific models which more closely approximate human biology, VistaGen is helping pharmaceutical companies more accurately assess how new drug therapies will perform in clinical trials. The Human Clinical Trials in a Test Tube platform also provides useful clinical data earlier in the drug development process – so drug companies will know sooner which drugs might work … and which drugs won’t. Having this information much sooner in the development cycle will help increase the efficiency of clinical trials and eliminate the waste of valuable resources.
For more information, visit VistaGen at www.VistaGen.com
Today's Top 3
The QualityStocks Public Company Sponsor News